Risk of psychiatric side effects with varenicline

BMJ (Online)

Volumn 339, Issue 7733, 2009, Pages 1272-

  Moore, Thomas J ^a   Furberg, Curt D ^b  

^a INSTITUTE FOR SAFE MEDICATION PRACTICES   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VARENICLINE;

ABNORMAL BEHAVIOR; AGGRESSION; BEHAVIOR CHANGE; DRUG FATALITY; DRUG RESEARCH; DRUG WITHDRAWAL; HALLUCINATION; HUMAN; LETTER; PATIENT MONITORING; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT; SUICIDAL IDEATION; SUICIDE; THINKING; TREATMENT WITHDRAWAL; VIOLENCE;

EID: 71749112686     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b4964     Document Type: Letter

References (5)

1. Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009;339:b3805. (1 October.) [Abstract/Free Full Text]
2. Medicines and Healthcare products Regulatory Agency. Download drug analysis prints. www.mhra.gov.uk/Safetyinformation/ Howwemonitorthesafetyofproducts/Medicines/TheYellowCardScheme/YellowCarddata/ Druganalysisprints/index.htm (accessed 9 October 2009)
3. Moore TJ, Cohen MR, Furberg CD. Strong safety signal seen for new varenicline risks. Institute for Safe Medication Practices. http://ismp.org/ QuarterWatch/chantixReport.asp (accessed 9 October 2009)
4. US Food and Drug Administration. Information for healthcare professionals: Varenicline (marketed as Chantix) and bupropion (marketed as Zyban, Wellbutrin, and generics). www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeath,careProfessionals/ucm169986.htm (accessed 9 October 2009).
5. Health Canada. New safety information regarding Champix (varenicline tartrate) - for the public. www.hcsc.gc.ca/dhp-mps/medeff/advisories-avis/ public/-2008/champix-pc-cp-eng.php (accessed 9 October 2009).